{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T04:17:33Z","timestamp":1743913053926,"version":"3.40.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bausch Health, Canada Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s13555-025-01369-3","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:17:42Z","timestamp":1742293062000},"page":"949-962","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Brodalumab for Plaque Psoriasis in the Canadian Real-World Setting: A Retrospective Cohort Analysis of up to 4 Years"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1285-7453","authenticated-orcid":false,"given":"Veronique","family":"Gaudet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8654-9050","authenticated-orcid":false,"given":"Irina","family":"Turchin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles W.","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dusan","family":"Sajic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3040-9988","authenticated-orcid":false,"given":"Shazia","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-2474","authenticated-orcid":false,"given":"Belinda","family":"Yap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3000-2125","authenticated-orcid":false,"given":"Maxime","family":"Barakat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8315-2522","authenticated-orcid":false,"given":"Vimal H.","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"3","key":"1369_CR1","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s13555-021-00518-8","volume":"11","author":"KA Papp","year":"2021","unstructured":"Papp KA, Gniadecki R, Beecker J, et al. Psoriasis prevalence and severity by expert elicitation. Dermatol Ther (Heidelb). 2021;11(3):1053\u201364. https:\/\/doi.org\/10.1007\/s13555-021-00518-8.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"1369_CR2","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/acr.23743","volume":"71","author":"L Eder","year":"2019","unstructured":"Eder L, Widdifield J, Rosen CF, et al. Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: a population-based study. Arthritis Care Res (Hoboken). 2019;71(8):1084\u201391. https:\/\/doi.org\/10.1002\/acr.23743.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1369_CR3","unstructured":"Canadian Psoriasis Guidelines Committee. Canadian Guidelines for the Management of Plaque Psoriasis, June 2009. http:\/\/www.dermatology.ca\/psoriasisguidelines. Accessed 4 Jul 2024."},{"key":"1369_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub6","author":"E Sbidian","year":"2023","unstructured":"Sbidian E, Chaimani A, Guelimi R, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2023. https:\/\/doi.org\/10.1002\/14651858.CD011535.pub6.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"1369_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s13555-021-00647-0","volume":"12","author":"AW Armstrong","year":"2022","unstructured":"Armstrong AW, Soliman AM, Betts KA, et al. Long-term benefit-risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther (Heidelb). 2022;12(1):167\u201384. https:\/\/doi.org\/10.1007\/s13555-021-00647-0.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1369_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s13555-022-00690-5","volume":"12","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Gooderham M, Griffiths CEM, et al. Cumulative clinical benefits of biologics in the treatment of patients with moderate-to-severe psoriasis over 1\u00a0year: a network meta-analysis. Dermatol Ther (Heidelb). 2022;12(3):727\u201340. https:\/\/doi.org\/10.1007\/s13555-022-00690-5.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1369_CR7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.36849\/JDD.2020.4957","volume":"19","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Wu JJ, Armstrong A, Menter A, Liu C, Jacobson A. Importance of complete skin clearance in psoriasis as a treatment goal: implications for patient-reported outcomes. J Drugs Dermatol. 2020;19(5):487\u201392.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"1369_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.36849\/JDD.2020.4645","volume":"19","author":"L Green","year":"2020","unstructured":"Green L, Weinberg JM, Menter A, Soung J, Lain E, Jacobson A. Clinical and molecular effects of interleukin-17 pathway blockade in psoriasis. J Drugs Dermatol. 2020;19(2):138\u201343. https:\/\/doi.org\/10.36849\/JDD.2020.4645.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"1369_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, et al. A prospective phase\u00a0III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273\u201386. https:\/\/doi.org\/10.1111\/bjd.14493.","journal-title":"Br J Dermatol"},{"issue":"14","key":"1369_CR10","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, et al. Phase\u00a03 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1503824.","journal-title":"N Engl J Med"},{"key":"1369_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1196966","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, Ibba L, Malagoli P, et al. Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3\u00a0years multicenter retrospective study-IL PSO (Italian landscape psoriasis). Front Med (Lausanne). 2023. https:\/\/doi.org\/10.3389\/fmed.2023.1196966.","journal-title":"Front Med (Lausanne)"},{"key":"1369_CR12","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S423234","author":"S Cacciapuoti","year":"2023","unstructured":"Cacciapuoti S, Potestio L, Guerrasio G, et al. Effectiveness of brodalumab in patients with moderate-to-severe plaque psoriasis located in difficult-to-treat areas. Clin Cosmet Investig Dermatol. 2023. https:\/\/doi.org\/10.2147\/CCID.S423234.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"9","key":"1369_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15667","volume":"35","author":"M Megna","year":"2022","unstructured":"Megna M, Potestio L, Camela E, Fabbrocini G, Ruggiero A. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;35(9): e15667. https:\/\/doi.org\/10.1111\/dth.15667.","journal-title":"Dermatol Ther"},{"issue":"4","key":"1369_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/jdv.18825","volume":"37","author":"N Rompoti","year":"2023","unstructured":"Rompoti N, Politou M, Stefanaki I, et al. Brodalumab in plaque psoriasis: real-world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104\u00a0weeks. J Eur Acad Dermatol Venereol. 2023;37(4):689\u201397. https:\/\/doi.org\/10.1111\/jdv.18825.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1369_CR15","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/jdv.19816","volume":"38","author":"D Rigopoulos","year":"2024","unstructured":"Rigopoulos D, Tampouratzi E, Angelakopoulos C, et al. Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the Br IDGE study). J Eur Acad Dermatol Venereol. 2024;38(6):1121\u201330. https:\/\/doi.org\/10.1111\/jdv.19816.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1369_CR16","doi-asserted-by":"publisher","first-page":"2340107","DOI":"10.1080\/09546634.2024.2340107","volume":"35","author":"L Schaeffer","year":"2024","unstructured":"Schaeffer L, Ben-Anaya N, Sorbe C, Rustenbach SJ, Mrowietz U, Augustin M. Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest. J Dermatolog Treat. 2024;35(1):2340107. https:\/\/doi.org\/10.1080\/09546634.2024.2340107.","journal-title":"J Dermatolog Treat"},{"key":"1369_CR17","unstructured":"Brodalumab (SILIQ\u00ae). Canadian Product Monograph. Bausch Health, Canada Inc. April 18, 2024. https:\/\/pdf.hres.ca\/dpd_pm\/00075300.PDF Accessed on 2024 Jul 4."},{"key":"1369_CR18","unstructured":"Guidance for Reporting Real-World Evidence. Ottawa (ON): CADTH; 2023: https:\/\/cadth.ca\/sites\/default\/files\/RWE\/MG0020\/MG0020-RWE-Guidance-Report-Secured.pdf Accessed 2024 July 4."},{"issue":"3","key":"1369_CR19","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1177\/12034754231168851","volume":"27","author":"V Gaudet","year":"2023","unstructured":"Gaudet V, Yap B, Hassan S, Barbeau M. Brodalumab for plaque psoriasis: a Canadian real-world experience at 2-years post-launch. J Cutan Med Surg. 2023;27(3):226\u201335. https:\/\/doi.org\/10.1177\/12034754231168851.","journal-title":"J Cutan Med Surg"},{"issue":"7","key":"1369_CR20","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1111\/ijd.17038","volume":"63","author":"L Mastorino","year":"2024","unstructured":"Mastorino L, Dapavo P, Burzi L, et al. Drug survival, effectiveness, and safety of brodalumab for moderate-to-severe psoriasis up to 3\u00a0years. Int J Dermatol. 2024;63(7):922\u20138. https:\/\/doi.org\/10.1111\/ijd.17038.","journal-title":"Int J Dermatol"},{"issue":"5","key":"1369_CR21","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s13555-024-01162-8","volume":"14","author":"MG Lebwohl","year":"2024","unstructured":"Lebwohl MG, Koo JY, Armstrong AW, et al. Brodalumab: 5-year US pharmacovigilance report. Dermatol Ther (Heidelb). 2024;14(5):1349\u201357. https:\/\/doi.org\/10.1007\/s13555-024-01162-8.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01369-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01369-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01369-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T14:54:30Z","timestamp":1743864870000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01369-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1369"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01369-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Veronique Gaudet and Maxime Barakat are employees at Bausch Health, Canada Inc. Innomar Strategies, Inc. received consulting fees from Bausch Health, Canada Inc., and is the employer of Belinda Yap and Shazia Hassan. Dr. Irina Turchin has been advisor, consultant, speaker and\/or investigator for Abbvie, Amgen, Arcutis, Bausch Health, BMS, Boehringer Ingelheim, Eli Lilly and Company, Galderma, Incyte, Janssen, Kiniksa, LEO Pharma, Mallinckrodt, Novartis, Pfizer, Sanofi Genzyme, Sun Pharma, and UCB. Dr. Charles W. Lynde has been a speaker and\/or consultant to: AbbVie, Amgen, Aralez, Arcutis, Bausch Health, Bayer, Bioderma, BioJAMP, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, CeraVe, Cipher, Dermavant, Eli Lilly, Fresnius Kabi, Galderma, GSK, InCyte, Innovaderm, InCyte, Intega Skin, Janssen, Kyowa Kirin, La Roche Posay, LEO Pharma, L\u2019Oreal, Medexus, MedX, Merck, Naos, Novartis, P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, SkinCeuticals, SunPharma, Takeda, TEVA, Tribute, UCB, Valeant, Viatris, Volo Health. Dr. Charles W. Lynde has been a principal investigator for: AbbVie, Acelyrin, Akros, Altius, Amgen, Aralez, Arcutis, Avillion, Bausch Health, Bioderma, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cipher, Concert, Dermavant, Devonian, Eli Lilly, Evelo, Galderma, GSK, InCyte, InCyte, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche Posay, LEO Pharma, L\u2019Oreal, Medexus, MedX, Merck, MoonLake, Naos, Nimbus, Novartis, P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, SunPharma, Takeda, TEVA, Tribute, UCB, Valeant, Viatris, Volo Health. Dr. Virginie Kelly has been advisor, consultant, speaker and\/or investigator for: AbbVie, Allakaos, Amgen, Appolo, Aslan pharmaceuticals, Bausch Health, Cara, ConCERT pharmaceuticals, Galderma, GSK, Horizon, Incyte, Inmagene, Innovaderm, Janssen, Laroche-Posay, Leo pharma, Lily, L\u2019Or\u00e9al, Nektar, Novartis, Numab, Opsidio, Pfizer, RAPT, Sanofi, Sun pharma, UCB, Verasci. Dr. Dusan Sajic has been advisor, consultant, speaker and\/or investigator for: Abbvie, Actilion, Bausch Health, Concert, Derma Research Group, Galderma, Jassen, Leo, Lilly, Novartis, Sun Pharma, UCB. Dr. Vimal H. Prajapati has been an advisor, consultant, speaker, and\/or investigator for AbbVie, Actelion, Amgen, AnaptysBio, Apogee Therapeutics, Aralez, Arcutis, Arena, Asana, Aspen, Bausch Health\/Valeant, Boehringer Ingelheim, BMS, Celgene, Cipher, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly and Company, Galderma, GSK, Homeocan, Incyte, Janssen, Johnson & Johnson, LEO Pharma, Medexus, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Organon, Pediapharm, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Sanofi Genzyme, Sun Pharma, Takeda, Tribute, UCB, and Vyne Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Patient consent to use data for analysis was obtained at the time of enrollment into the PSP, and only non-identifiable patient data were collected and analyzed in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}